Avidity biosciences completes enrollment in biomarker cohort in phase 1/2 fortitude™ trial for delpacibart braxlosiran (del-brax) in people living with facioscapulohumeral muscular dystrophy

Del-brax fortitude biomarker cohort designed for potential accelerated approval; plan to share regulatory update in q2 2025 regulatory alignment on global phase 3 del-brax trial design and study initiation anticipated in q2 2025 plan to present topline data from fortitude dose escalation cohorts in q2 2025 on track to be first globally approved drug for fshd san diego , march 31, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the completion of enrollment in the biomarker cohort in the phase 1/2 fortitude™ clinical trial of delpacibart braxlosiran (del-brax) in people living with facioscapulohumeral muscular dystrophy (fshd). a total of 51 participants were enrolled in the fortitude biomarker cohort.
RNA Ratings Summary
RNA Quant Ranking